Updated for 2026
REx-PN pharmacology: medication safety and administration for Canadian RPNs
Pharmacology knowledge is embedded throughout the REx-PN. The Canadian RPN/PN administers medications safely within regulated scope, monitors for therapeutic and adverse effects, and educates patients about their medications. NCJMM clinical judgment is applied to medication administration decisions throughout the exam.
Educational purpose: This content is for exam preparation and professional development only. It is not intended for clinical decision-making. Always follow current guidelines, institutional policies, and scope of practice.
Canadian drug regulatory context for REx-PN
The REx-PN uses Canadian drug references and regulatory context. Key differences from US-based pharmacology content:
Drug naming: Canadian drug products use Health Canada approved names. Some drug names differ from US brand or generic names. The Compendium of Pharmaceuticals and Specialties (CPS) is the primary Canadian drug reference.
Controlled substances: Scheduled under the Controlled Drugs and Substances Act (CDSA) — different scheduling from US DEA schedules. Opioids (Schedule I and II under CDSA), benzodiazepines, and stimulants have specific handling, documentation, and disposal requirements.
High-alert medications (ISMP Canada): ISMP Canada publishes the high-alert medications list specific to Canadian practice. Core list overlap with the US list: insulin, anticoagulants, opioids, concentrated electrolytes, neuromuscular blocking agents. Institutional double-check policies apply.
Rights of medication administration and PN accountability
The six rights of medication administration are tested within the Canadian RPN/PN accountability framework. The PN is accountable for medications they administer — not relieved of accountability by following an order if the order was clearly unsafe.
When to clarify or hold: Drug allergy not previously documented. Order falls outside expected therapeutic range with no explanation. Patient's current condition appears to contraindicate the ordered medication (e.g., antihypertensive ordered, patient hypotensive). Drug interaction is identified. Patient refuses the medication.
PN authority to question: The Canadian PN has both the right and the professional obligation to clarify questionable medication orders before administering. Contact the prescriber, consult the pharmacist, or escalate to the supervising RN. Document the query and response. This is not insubordination — it is safe practice.
Frequently asked questions
- Which high-alert medications appear most frequently on the REx-PN?
- The REx-PN most frequently tests: (1) Insulin — correct type verification, hypoglycaemia recognition, pre-meal glucose check protocol. (2) Anticoagulants — heparin monitoring (aPTT), warfarin monitoring (INR), bleeding precautions, enoxaparin (Lovenox) subcutaneous technique. (3) Opioids — RR monitoring before administration, naloxone availability, constipation prevention, sedation score monitoring. (4) Digoxin — apical pulse 60 seconds, toxicity signs, hold parameters. (5) Potassium chloride — IV never given undiluted/by push, rate limitations, monitoring requirements. These same principles apply to Canadian PN practice as international standards.
Clinically reviewed by NurseNest Clinical Review Team · Last updated 2026-06-10 · For educational purposes only · Review policy